3 of the Best ETFs to Buy and Hold if a Recession Is Coming

The article recommends three diversified ETFs for recession preparedness: Vanguard Healthcare ETF (VHT), Vanguard Total Bond Market ETF (BND), and Vanguard S&P 500 ETF (VOO). VHT offers defensive healthcare exposure through 416 holdings and a 0.09% expense ratio; BND holds 11,421 bonds, yields 5.1%, and could benefit if recession-driven Federal Reserve rate cuts lift bond prices. VOO may face greater near-term drawdowns but has returned 827% since September 2010, supporting the case for maintaining long-term equity exposure rather than selling during downturns.

Analysis

The relevant distinction is not “defensive” versus “cyclical,” but earnings-duration and valuation risk. VHT is increasingly a large-cap pharma/biotech factor exposure: LLY’s premium embeds sustained obesity-franchise execution, while ABBV and MRK carry patent-cliff and pipeline-reset risk that can dominate any recession resilience. A slowing-growth tape could favor JNJ and MRK over LLY and UNH, since premium-growth expectations and reimbursement-policy risk leave the latter two more exposed to estimate deratings.

BND is not a clean recession hedge unless disinflation, rather than credit stress, drives the easing cycle. Treasury duration should rally first over days to weeks if payroll or inflation data weaken, but its investment-grade credit sleeve can offset part of that gain if spreads widen materially; long-duration Treasuries such as EDV or TLT offer more direct policy-cut convexity. Conversely, a resilient labor market or renewed term-premium shock would leave BND vulnerable despite eventual Fed easing expectations.

The contrarian point is that broad-equity exposure may be less recession-sensitive than headline index beta suggests if nominal yields decline: MSFT, NVDA, AMZN and GOOG have cash-rich balance sheets and long-duration cash flows that can benefit from lower discount rates. That outcome fails in an earnings recession, however, where elevated megacap concentration turns VOO into a correlated AI/capex trade rather than a diversified recovery vehicle. This is a low-information retail-allocation article; absent a clear deterioration in leading indicators or credit spreads, it does not independently justify a major risk-off rotation.

Key Decisions for Investors

• Maintain a modest 1-3 month defensive tilt via long JNJ and MRK versus short an equal-dollar basket of XLY; use a 5-7% relative stop. The thesis is stable cash-flow visibility and lower valuation sensitivity, not a blanket long-healthcare call.
• For a confirmed disinflation shock, prefer a tactical long TLT or EDV over BND for 4-12 weeks; enter only after a downside inflation/payroll surprise and target a 75-100 bp decline in the 10-year yield. Exit if the 10-year yield rises 35 bp from entry or high-yield spreads widen above roughly 450 bp, which would shift the regime from rate relief to credit stress.
• Avoid adding to LLY solely as a recession hedge. Monitor obesity-drug volume, net-price realization, and 2027+ guidance; a material cut to those metrics would create downside disproportionate to VHT’s apparent diversification.
• If recession odds rise while real yields fall but credit remains orderly, express the quality-growth case through long MSFT/GOOG versus short IWM over 1-3 months. Close the pair if high-yield spreads move above 500 bp or either company guides cloud/advertising growth below consensus, signaling that earnings risk has overtaken duration support.